Who Owns Paxlovid?
Paxlovid is owned by Pfizer Inc. (NYSE: PFE), a publicly traded American pharmaceutical company headquartered in New York City. Paxlovid is a product brand within Pfizer's hospital and anti-infective portfolio, developed internally by Pfizer scientists. It received FDA emergency authorization in December 2021 and full approval for high-risk adults in May 2023.
Paxlovid Timeline
GlobalOfficial Website
Who Owns Paxlovid?
- Parent Company: Pfizer Inc.
- Ownership Type: Product line
- Company Type: Publicly Traded
- Stock Ticker: NYSE: PFE
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Paxlovid | Pfizer Inc. | Product line |
Where to Buy
Disclosure: We may earn commission from purchases
Paxlovid on AmazonHistory of Paxlovid
- Founded: 2021
- Founders: Pfizer Inc. (internal development)
Paxlovid's active agent, nirmatrelvir, is a protease inhibitor designed to block the SARS-CoV-2 main protease, the enzyme the virus requires to replicate. Pfizer scientists developed the compound rapidly in 2020 by modifying earlier protease inhibitor work the company had pursued against the original SARS virus two decades before. Ritonavir, an existing drug, is co-packaged to slow nirmatrelvir's metabolism and extend its effective concentration.
Pfizer announced the landmark EPIC-HR trial result in November 2021: an 89% reduction in hospitalization or death among high-risk patients treated within three days of symptom onset. The FDA issued emergency use authorization on December 22, 2021, making Paxlovid the first oral outpatient treatment for COVID-19 authorized in the United States.
Demand exploded in 2022 as governments stockpiled treatment courses. Paxlovid generated approximately $18.9 billion in revenue in 2022, briefly making it one of the largest-selling drugs in the world and a principal driver of Pfizer's record pandemic-era results.
Full FDA approval for adults at high risk of severe disease arrived in May 2023 as the emergency-use framework wound down. Sales then declined steeply with the end of government procurement and falling COVID-19 hospitalization rates, but Paxlovid remained a multi-billion-dollar product in Pfizer's FY2025 results within the company's $62.6 billion total revenue.
As of 2026, Paxlovid is sold commercially in the United States and internationally as a standard prescription antiviral, with Pfizer continuing label work on broader patient populations.
About Pfizer Inc.
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
- Founded: 1849
- Headquarters: New York, New York, USA
- Company Type: Publicly Traded
- Stock: NYSE: PFE
- Revenue: $62.6 billion (FY2025)
- Employees: approximately 88,000
Where Is Paxlovid Made / Based?
- Headquarters: New York, New York, USA
- Manufacturing / Operations: United States, Ireland, Italy
Paxlovid Categories & Tags
Paxlovid Recalls & Controversies
Paxlovid's main documented clinical controversy is the "rebound" phenomenon, in which COVID-19 symptoms and viral load return after completing a treatment course. Studies including the EPIC trials and CDC surveillance documented rebound rates in both treated and untreated patients, and FDA labeling addresses the phenomenon without restricting use.
The drug interaction profile has generated the most significant clinical criticism, with prescribing restrictions limiting the eligible population and requiring medication reconciliation that discourages some outpatient use.
Price has drawn scrutiny. Pfizer set the commercial US list price at approximately $1,390 per five-day course after government purchase contracts ended, attracting criticism from patient advocates and policymakers over cost relative to the drug's manufacturing economics. Pfizer maintains patient assistance programs and points to the drug's hospitalization cost offset.
Brands Owned by Pfizer Inc.
Healthcare PharmaceuticalsAbrysvo
Owned by Pfizer Inc.
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
rsv-vaccinevaccinesmaternal-immunization
Healthcare PharmaceuticalsAdcetris
Owned by Pfizer Inc.
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.
oncologyantibody-drug-conjugatelymphoma
Healthcare PharmaceuticalsCaduet
Owned by Pfizer Inc.
Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.
prescription-drugcardiovascularhypertension
Healthcare PharmaceuticalsCelebrex
Owned by Pfizer Inc.
Prescription COX-2 inhibitor anti-inflammatory medication for treating arthritis pain, originally developed by G.D. Searle & Company and now marketed by Pfizer.
pain-reliefanti-inflammatoryarthritis
Healthcare PharmaceuticalsChantix
Owned by Pfizer Inc.
Prescription smoking cessation medication (varenicline) developed by Pfizer, FDA-approved in 2006.
smoking-cessationvareniclinenicotinic-receptor
Healthcare PharmaceuticalsComirnaty
Owned by Pfizer Inc.
Pfizer-BioNTech COVID-19 mRNA vaccine, the first FDA-approved COVID vaccine in the United States, co-commercialized globally by Pfizer and BioNTech.
covid-19mrna-vaccinevaccines
Paxlovid Ownership: Pros & Cons
Advantages
- +Fully owned by Pfizer with no partner revenue split, unlike Comirnaty
- +First-mover oral antiviral with dominant share of the COVID-19 treatment market
- +Efficacy profile superior to the principal competitor, Merck's Lagevrio
- +Standard pharmaceutical supply chain with no cold-chain burden
Considerations
- -Revenue has collapsed from the 2022 peak and depends on unpredictable infection waves
- -Extensive drug interactions limit prescribing in the highest-risk elderly population
- -Commercial pricing has attracted affordability criticism
- -Uncertain long-term demand as COVID-19 severity declines in the general population
Frequently Asked Questions About Paxlovid
Sources & Further Reading
Competitors to Paxlovid
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Merck | USA | 2007 | Premium | Global | All Genders | |
| Pfizer | USA | 2021 | Mass market | Global | All Genders | |
| Roche | Switzerland | 1999 | Premium | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsIsentress
Owned by Merck & Co.
Prescription HIV antiretroviral medication (raltegravir) developed by Merck and Co., FDA-approved in 2007 as the first integrase strand transfer inhibitor for HIV-1 treatment.
hivantiretroviralintegrase-inhibitor
Healthcare PharmaceuticalsPaxlovid
Owned by Pfizer Inc.
Oral antiviral medication for COVID-19 containing nirmatrelvir and ritonavir, developed and marketed by Pfizer Inc. (NYSE: PFE). Received FDA Emergency Use Authorization in December 2021 and full approval in May 2023.
covid-19antiviralmedication
Healthcare PharmaceuticalsTamiflu
Owned by Roche
Oseltamivir antiviral medication invented by Gilead Sciences and licensed to Roche in 1996. FDA approved in 1999 for influenza treatment and prevention. U.S. patent expired in 2016, with generic oseltamivir now widely available.
antiviralinfluenzaoseltamivir
Competitive Analysis
Market Positioning: Paxlovid competes with 3 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Paxlovid
Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Paxlovid which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike Paxlovid which is under a publicly traded parent company.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Paxlovid which is under a publicly traded parent company.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike Paxlovid which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Paxlovid which is under a publicly traded parent company.
Healthcare PharmaceuticalsWalgreens
Owned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
pharmacydrugstoreretail-pharmacy
Privately Owned
Walgreens is privately owned, unlike Paxlovid which is under a publicly traded parent company.
Pfizer Inc. Stock Information
Jobs at Pfizer Inc.
Latest News About Paxlovid
Related Articles About Paxlovid
View more articles
Industry Analysis
Brands That Relocated Headquarters for Tax Reasons
From Pfizer's failed Irish inversion to ExxonMobil's Texas move, discover why brands relocate their headquarters for tax and legal reasons — and how it affects their brand portfolios. Explore our database.
Who Brands StaffMay 22, 2026
TaxHeadquartersCorporate Relocation
Industry Analysis
How Government Policy Shapes Brand Ownership
From antitrust rulings to tariff wars, government policy determines which brands get acquired, which get blocked, and which stay independent. Our guide explains how policy shapes brand ownership. Explore our database.
Who Brands StaffMay 17, 2026
GovernmentPolicyAntitrust
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription